MXCT - MaxCyte Inc

MXCT - MaxCyte Inc

https://www.maxcyte.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - C3.ai ( NYSE:AI ) , Aspen Aerogels ( NYSE:ASPN )

Benzinga • 1 month ago • score: 0.18

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst James Heaney downgraded The Trade Desk, Inc.

MaxCyte, Inc. ( MXCT ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.05

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

GlobeNewswire • 2 months ago • score: 0.27

ROCKVILLE, Md., July 09, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it ...

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

GlobeNewswire • 3 months ago • score: 0.40

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten ...

MaxCyte, Inc. ( MXCT ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.10

MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

GlobeNewswire • 5 months ago • score: 0.42

ROCKVILLE, Md., April 10, 2025 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., ( NASDAQ: MXCT. LSE: MXCT ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

None

52W High

$5.20

52W Low

$1.26

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.29

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-11.07

EV/Revenue (<3 favorable)

1.18

P/S (TTM) (<3 favorable)

4.20

P/B (<3 favorable)

0.79

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.77%

Institutions (25–75% balanced)

75.32%

Shares Outstanding

106,607,000

Float

96,185,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

35,754,000

Gross Profit (TTM)

28,529,000

EPS (TTM)

-0.42

Profit Margin (>10% good)

-1.25%

Operating Margin (TTM) (higher better)

-1.67%

ROE (TTM) (>15% strong)

-0.22%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.18

Momentum

Bearish momentum

Value

-0.0815

Previous

-0.0917

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025